Strategic Growth Target CDMO CRO buyers in mid-size pharma manufacturing who need particle engineering, spray drying, and supercritical precipitation capabilities to scale early-stage to Phase III cGMP production, highlighting CritiTech as a rapid-growth partner with broad service scope.

Innovative Technology Position CritiTech’s Purcision technology and expertise in particle engineering as differentiators for customers seeking improved drug delivery and next-generation particle formulations, including inhaled niclosamide opportunities and potential collaborations.

Recognition & Awards Leverage recent 2025 Juried Award for Most Promising Drug Delivery Technology to build credibility with prospective clients and strategic partners, signaling market leadership in drug delivery technologies.

Collaborative Partnerships Highlight past and ongoing collaborations (Aeon Respire, NanOlogy) to illustrate a track record of co-development and innovation, appealing to biotech firms seeking joint development for inhaled and local delivery solutions.

Market Positioning Emphasize mid-market service scale and revenue range to align with smaller biotech and emerging pharma companies seeking flexible, end-to-end manufacturing and analytical testing support without the burden of large CMO contracts.